Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 48 for your search:
Start Over
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0848, NCI-2011-01987, CDR0000659092, NCT01013649
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 20 and over
Trial IDs: U31287-A-U301, NCI-2014-01446, NCT02134015
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: 15296, NCI-2014-02441, 2013-004662-33, I3Y-MC-JPBK, NCT02152631
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, U1111-1160-2242, NCT02296125
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15540, NCI-2016-00365, 2014-004824-22, I4T-MC-JVCY, NCT02411448
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 8273-CL-0302, NCI-2016-00113, 2015-002894-39, NCT02588261
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 60107, NCI-2009-01250, CCCWFU-IRB00003457, CDR0000578838, LILLY-CCCWFU-60107, NCT01580449, P30CA012197, NCT00573989
Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-058, NCI-2011-02501, NCT01233687
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
Alisertib and Erlotinib Hydrochloride in Treating Patients with Recurrent Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-036, NCI-2011-03306, FER-TH-036, X14004, NCT01471964
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pacritinib and Erlotinib Hydrochloride in Treating Patients with Metastatic or Locally Advanced Non-small Cell Lung Cancer after EGFR TKI Treatment
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201503052, NCI-2015-00399, J20001, NCT02342353
A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BGBC004, NCI-2015-00730, NCT02424617
Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients with Recurrent or Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHI-80, NCI-2015-01411, 9878, NCT02535338
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Erlotinib Hydrochloride, Akt Inhibitor MK2206, Selumetinib, or Sorafenib Tosylate in Treating Patients with Previously Treated Stage III-IV Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-0360, NCI-2011-01104, NCT01248247
GSK1120212 Rollover Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Erlotinib Hydrochloride with or without Bevacizumab in Treating Patients with Stage IV Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RC1126, NCI-2012-00053, 11-006881, Mod11-006881-13, NCT01532089
Ascorbic Acid, Gemcitabine Hydrochloride, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 11D.365, NCI-2012-00340, 2008-52(1), NCT01555489
Erlotinib Hydrochloride in Treating Patients with Malignant Peritoneal Mesothelioma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0032, NCI-2012-00332, NCT01592383
Start Over